NASDAQ$OPK
OPKO Health Inc · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
OPKO Health's Q4 2019 financial results were reported, with revenue increase and ongoing clinical trials.
OPKO Health reported an increase in consolidated revenues for Q4 2019 to $224.3 million compared to $221.9 million in Q4 2018. The net loss for the quarter was $112.4 million, or $0.18 per share, compared to a net loss of $76.1 million, or $0.13 per share, for the comparable period of 2018. The company's cash, cash equivalents, and marketable securities totaled $85.5 million as of December 31, 2019.
- Phase 3 trial for Somatrogon met its primary endpoint.
- Total prescriptions for RAYALDEE increased by 89% compared to Q4 2018.
- 4Kscore test received final Local Coverage Determination for Medicare payments.
- Consolidated revenues increased to $224.3 million compared to the same period in 2018.
Headline financials
Revenue & EPS history
OPKO Health · Revenue · Quarterly
$224M
Revenue by segment
OPKO Health · $224M total across 3 segments · Q4 2019
- Services$178M—79.3%
- Products$32M—14.3%
- IP & Other$14.4M—6.4%
Forward guidance
OPKO Health anticipates regulatory submission in the U.S. for Somatrogon in 2H 2020, with Europe expected to follow upon completion of an open-label study in Q3 2020. The registration study in pediatric GHD patients in Japan is on track for completion in Q1 2020. An interim readout of the Phase 2 trial with RAYALDEE in adults with vitamin D insufficiency and stage 5 chronic kidney disease (CKD) requiring dialysis is expected in Q1 2020.
Tailwinds
- Regulatory submission in the U.S. for Somatrogon anticipated in 2H 2020.
- Europe is expected to follow upon completion of the open-label study in Q3 2020.
- Registration study in pediatric GHD patients in Japan is on track for completion in Q1 2020.
- Interim readout of the Phase 2 trial with RAYALDEE expected in Q1 2020.
- Company entered into an unsecured credit facility providing $100 million of incremental capital on a non-dilutive basis.
Headwinds
- Possibility of unfavorable new clinical data.
- Risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities.
- Uncertainty whether regulatory authorities will be satisfied with the design of and results from clinical studies.
- Risk inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments.
- Forward-looking statements may be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2019
-0.7%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-0.2%
Avg return
30 days after
44%
27 / 61 earnings
Positive
+26.8%
Q1 2018
Best reaction
-17.7%
Q3 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.8% | -8.3% | +19.2% | |
| Q4 2025 | +2.5% | +0.0% | -6.7% | |
| Q3 2025 | -2.9% | -4.3% | -2.9% | |
| Q1 2025 | -2.2% | -7.2% | -1.4% | |
| Q4 2024 | +6.7% | +19.0% | +4.3% | |
| Q3 2024 | +3.4% | +9.5% | +8.2% | |
| Q2 2024 | +6.7% | +11.9% | +16.4% | |
| Q1 2024 | -5.3% | -3.0% | +1.5% | |
| Q4 2023 | -1.1% | -1.0% | +20.0% | |
| Q3 2023 | -0.7% | -6.7% | +18.5% | |
| Q2 2023 | +13.1% | +6.8% | +2.8% | |
| Q1 2023 | +15.0% | +26.5% | -1.4% | |
| Q4 2022 | +0.0% | +7.5% | +22.6% | |
| Q3 2022 | -14.8% | -9.3% | -25.8% | |
| Q2 2022 | -6.6% | +2.9% | -12.7% | |
| Q1 2022 | +11.8% | +15.6% | +8.4% | |
| Q4 2021 | +7.4% | +3.7% | +17.8% | |
| Q3 2021 | +5.9% | +16.2% | +15.4% | |
| Q2 2021 | -11.6% | -7.2% | -0.8% | |
| Q1 2021 | -3.7% | -4.2% | -10.5% | |
| Q4 2020 | -13.6% | -18.0% | -12.9% | |
| Q3 2020 | -12.0% | -11.0% | +3.3% | |
| Q2 2020 | -11.1% | -7.4% | -42.3% | |
| Q1 2020 | -15.2% | +3.9% | +2.2% | |
| Q4 2019 | +3.6% | +12.2% | +0.7% | |
| Q3 2019 | -2.0% | -2.6% | +5.3% | |
| Q2 2019 | -2.1% | -6.2% | -4.6% | |
| Q1 2019 | -16.1% | -14.9% | -22.1% | |
| Q4 2018 | -9.9% | -5.7% | -7.8% | |
| Q3 2018 | +6.7% | -7.4% | -6.0% | |
| Q2 2018 | -0.4% | -1.6% | +1.5% | |
| Q1 2018 | +26.8% | +37.8% | +23.5% | |
| Q4 2017 | -0.6% | +0.9% | -6.5% | |
| Q3 2017 | -17.7% | -20.1% | -20.2% | |
| Q2 2017 | +1.7% | -1.3% | -1.6% | |
| Q1 2017 | -3.4% | -0.8% | -13.7% | |
| Q4 2016 | -11.5% | -9.3% | -4.6% | |
| Q3 2016 | -6.6% | -3.4% | +11.8% | |
| Q2 2016 | +0.3% | -0.5% | -5.1% | |
| Q1 2016 | +6.7% | — | — | |
| Q4 2015 | +0.4% | — | — | |
| Q3 2015 | +7.6% | — | — | |
| Q2 2015 | -13.7% | — | — | |
| Q1 2015 | +4.8% | — | — | |
| Q4 2014 | -2.7% | — | — | |
| Q3 2014 | +2.5% | — | — | |
| Q2 2014 | -4.0% | — | — | |
| Q1 2014 | +8.4% | — | — | |
| Q4 2013 | -0.6% | — | — | |
| Q3 2013 | -1.4% | — | — | |
| Q2 2013 | +3.7% | — | — | |
| Q1 2013 | +3.4% | — | — | |
| Q4 2011 | -4.0% | — | — | |
| Q1 2011 | +1.3% | — | — | |
| Q1 2012 | +2.7% | — | — | |
| Q4 2009 | -2.6% | — | — | |
| Q3 2011 | -2.3% | — | — | |
| Q2 2011 | -3.3% | — | — | |
| Q4 2010 | -3.3% | — | — | |
| Q3 2010 | +0.7% | — | — | |
| Q1 2010 | +9.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro